Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study
暂无分享,去创建一个
T. Sterling | R. Belknap | E. Nuermberger | Nicole C. Ammerman | Kendra K. Radtke | R. Savic | R. Boyd | N. Zhang | Jacqueline P. Ernest
[1] K. Dooley,et al. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. , 2020, American journal of respiratory and critical care medicine.
[2] M. Behr,et al. Is Mycobacterium tuberculosis infection life long? , 2019, BMJ.
[3] C. Kuo,et al. Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI , 2019, Journal of clinical medicine.
[4] R. Chaisson,et al. One Month of Rifapentine plus Isoniazid to Prevent HIV‐Related Tuberculosis , 2019, The New England journal of medicine.
[5] M. Behr,et al. Revisiting the timetable of tuberculosis , 2018, British Medical Journal.
[6] R. Long,et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults , 2018, The New England journal of medicine.
[7] K. Dooley,et al. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? , 2017, Expert review of clinical pharmacology.
[8] J. Ernst,et al. The Challenge of Latent TB Infection. , 2016, JAMA.
[9] T. Sterling,et al. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[10] T. Sterling,et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] K. Dooley,et al. Population Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Healthy Volunteers: Nonlinearities in Clearance and Bioavailability , 2014, Antimicrobial Agents and Chemotherapy.
[12] Vijay T. Ahuja,et al. Effect of repeated dosing on rifampin exposure in BALB/c mice. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[13] Robert J Wilkinson,et al. The immune response in tuberculosis. , 2013, Annual review of immunology.
[14] J. Hackman,et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. , 2011, The New England journal of medicine.
[15] H. McIlleron,et al. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. , 2011, British journal of clinical pharmacology.
[16] D. Mitchison,et al. Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male Volunteers , 2010, Antimicrobial Agents and Chemotherapy.
[17] T. Sterling,et al. Latent TB infection treatment acceptance and completion in the United States and Canada. , 2010, Chest.
[18] J. Grosset,et al. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. , 2009, American journal of respiratory and critical care medicine.
[19] G. Drusano,et al. Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin , 2007, Antimicrobial Agents and Chemotherapy.
[20] W. Bishai,et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. , 2006, American journal of respiratory and critical care medicine.
[21] E. Kantharaj,et al. Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.
[22] D. Snider,et al. Isoniazid-associated hepatitis deaths: a review of available information. , 1992, The American review of respiratory disease.
[23] A. Assandri,et al. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. , 1984, The Journal of antibiotics.
[24] D. Snider,et al. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. , 1978, The American review of respiratory disease.
[25] Norman L. Cressy. The Tubercle Bacillus in the Pulmonary Lesion of Man , 1955, The Yale Journal of Biology and Medicine.
[26] Opie,et al. Tubercle Bacilli in Latent Tuberculous Lesions in Lung Tissue without Tuberculous Lesions , 1928 .